Neuroone Medical Technologies (NMTC) Corporate presentation summary

Technology and product innovation

• Platform thin-film electrode technology enables both diagnostic and therapeutic applications, with FDA clearance for four product families including SEEG and cortical electrodes, and ablation systems for brain and trigeminal nerve procedures.

• Multi-purpose electrodes reduce surgeries and hospitalizations, offering improved efficacy and less invasive placement due to flexible thin-film design.

• Only FDA-cleared device allowing both diagnosis and radiofrequency ablation using the same SEEG electrode.

• Drug delivery system leverages SEEG platform for simultaneous brain activity recording and therapeutic agent delivery, with commercialization for animal and IDE studies targeted by end of Q2 2026.

• Product portfolio addresses multi-billion dollar markets in epilepsy, Parkinson's, back pain, and drug delivery.

Strategic partnerships and commercialization

• Exclusive partnerships with Zimmer Biomet for robotic neurosurgery and Mayo Clinic for clinical research and advisory leadership.

• Zimmer Biomet partnership has generated $8.5M in licensing revenue and expanded to include distribution of the OneRF Ablation System.

• Mayo Clinic conducted initial technology testing and first commercial use of Evo Cortical Electrodes; key Mayo Clinic neurologists and neurosurgeons serve on the advisory board.

• Preparing for international commercialization and ISO 13485 certification to enable global product shipments.

Financial performance and outlook

• Q1 FY2026 product revenue reached $2.9M, up 5.5% sequentially, with a gross margin of 54.2%.

• Debt-free balance sheet with $3.6M in cash and $2.7M in accounts receivable as of 12/31/25.

• Expects product revenue to increase to at least $10.5M in fiscal year 2026, driven by new product launches and partnerships.

• Potential for non-dilutive licensing agreements and strategic partnerships in pain management and drug delivery.